Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIVERSALRBA: DTG and F/TAF Pediatric Formulation PK Study
NCT05489406Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Relative bioavailability of tenofovir alafenamide and tenofovir at 17 days, Relative bioavailability of emtricitabine at 17 days and 2 more. Started Oct 2022; status: completed.
02
Drugs
dolutegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05489406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489406.